From The Stage

The Power of Being NYCE

Dr. Jim McNally
Posted by Dr. Jim McNally / / Gene Therapy, Industry Update

A recent study using triple-edited ‘NYCE’ cells shows the possibilities of multiplex genome editing to effectively treat complex diseases like some cancers. We explore the promising results.

Science Can’t Be Stopped: Pushing Forward Health Breakthroughs & Hope in Uncertain Times

Dr. Afshin Safavi
Posted by Dr. Afshin Safavi / / Industry Update

As the pharma & biotech industry is working around the clock to address the unprecedented COVID-19 health crisis, they are also giving the world hope that we will overcome these trying times. We highlight some of the important solutions in development & why we're all pushing forward: because to create new breakthroughs, you can't stop science.

A Dose of Pharma and Biotech News: December 12, 2019

Jim Datin
Posted by Jim Datin / / BioAgilytix Insight, Industry Update

With innovative research driving pharmaceutical and biotech breakthroughs, industry progress is accelerating at a rapid pace. We've compiled some recent industry articles on the latest topics to share with you.

C-Path “Points to Consider Document” Clarifies Bioanalytical Assay Validation in Support of Clinical Biomarker Qualification

Dr. Afshin Safavi
Posted by Dr. Afshin Safavi / / Biomarkers, Industry Update

A contributing author to the Critical Path Institute (C-Path)’s “Points to Consider Document,” Dr. Afshin Safavi summarizes considerations outlined in the paper designed to establish consensus on the expectations for the validation of assays used in the regulatory qualification of fluid biomarkers.